M
Michael Muchow
Researcher at University of Maryland, College Park
Publications - 15
Citations - 957
Michael Muchow is an academic researcher from University of Maryland, College Park. The author has contributed to research in topics: Anterior pituitary & Germline mutation. The author has an hindex of 11, co-authored 15 publications receiving 896 citations. Previous affiliations of Michael Muchow include National Institute of Standards and Technology & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD.
Barbara Pasini,Sarah R. McWhinney,Thalia Bei,Ludmila Matyakhina,Sotirios Stergiopoulos,Michael Muchow,Sosipatros Boikos,Barbara Ferrando,Karel Pacak,Guillaume Assié,Guillaume Assié,Eric Baudin,Agnès Chompret,Jay W. Ellison,Jean Jacques Briere,Jean Jacques Briere,Pierre Rustin,Pierre Rustin,Anne Paule Gimenez-Roqueplo,Anne Paule Gimenez-Roqueplo,Charis Eng,Charis Eng,J. Aidan Carney,Constantine A. Stratakis +23 more
TL;DR: It is concluded that succinate dehydrogenase deficiency may be the cause of a subgroup of GISTs and this offers a therapeutic target for Gists that may not respond to STI571 and its analogs.
Journal ArticleDOI
Genetics of Carney Triad: Recurrent Losses at Chromosome 1 but Lack of Germline Mutations in Genes Associated with Paragangliomas and Gastrointestinal Stromal Tumors
Ludmila Matyakhina,Thalia Bei,Sarah R. McWhinney,Barbara Pasini,Silke Cameron,Bastian Gunawan,Sotirios Stergiopoulos,Sosipatros Boikos,Michael Muchow,Amalia Dutra,Evgenia Pak,Elias Campo,Maria C. Cid,Fulgencio Gomez,Rolf C. Gaillard,Guillaume Assié,Guillaume Assié,László Füzesi,Bora E. Baysal,Charis Eng,Charis Eng,J. Aidan Carney,Constantine A. Stratakis +22 more
TL;DR: Investigating the possibility that patients with CT and/or their tumors may harbor mutations of the SDHB, SDHC, SDHD, KIT, and PDGFRA genes and identifying any other genetic alterations in CT tumors concluded that CT is not due to SDH-inactivating or KIT- andPDGFRA-activating mutations.
Journal ArticleDOI
Protein kinase A effects of an expressed PRKAR1A mutation associated with aggressive tumors.
Elise Meoli,Ioannis Bossis,Laure Cazabat,Manos Mavrakis,Anelia Horvath,Sotiris Stergiopoulos,Miriam L. Shiferaw,Glawdys Fumey,Karine Perlemoine,Michael Muchow,Audrey Robinson-White,Frank Weinberg,Maria Nesterova,Yianna Patronas,Lionel Groussin,Jérôme Bertherat,Constantine A. Stratakis +16 more
TL;DR: It is concluded that R1 alpha Delta 6 leads to increased PKA activity through the mt-R1 alpha decreased binding to C alpha and does not involve changes in other PKA subunits, suggesting that a switch to type II PKAactivity is not necessary for increased kinase activity or tumorigenesis.
Journal ArticleDOI
Gene expression profiling during cellular differentiation in the embryonic pituitary gland using cDNA microarrays
Laura E. Ellestad,Wilfrid Carre,Michael Muchow,Sultan A. Jenkins,Xiaofei Wang,Larry A. Cogburn,Tom E. Porter +6 more
TL;DR: This is the first study to evaluate changes in anterior pituitary gene expression during embryonic development of any species using microarrays, and numerous transcription factors and signaling molecules not previously implicated in pituitARY development were identified.
Journal ArticleDOI
Mouse Prkar1a haploinsufficiency leads to an increase in tumors in the Trp53+/− or Rb1+/− backgrounds and chemically induced skin papillomas by dysregulation of the cell cycle and Wnt signaling
Madson Q. Almeida,Michael Muchow,Sosipatros Boikos,Andrew J. Bauer,Kurt J. Griffin,Kit Man Tsang,Chris Cheadle,Tonya Watkins,Feng Wen,Matthew F. Starost,Ioannis Bossis,Maria Nesterova,Constantine A. Stratakis +12 more
TL;DR: PKR1a haploinsufficiency is a relatively weak tumorigenic signal that can act synergistically with other tumor suppressor gene defects or chemicals to induce tumors, mostly through Wnt-signaling activation and cell cycle dysregulation, consistent with studies in human neoplasms carrying PRKAR1A defects.